Trade

with

Cubist Pharmaceuticals Inc
(NASDAQ: CBST)
AdChoices
67.14
-0.21
-0.31%
After Hours :
-
-
-

Open

67.13

Previous Close

67.35

Volume (Avg)

2.56k (726.94k)

Day's Range

66.83-67.58

52Wk Range

58.50-82.12

Market Cap.

5.10B

Dividend Rate ( Yield )

-

Beta

0.75

Shares Outstanding

75.73M

P/E Ratio (EPS)

625.00 (0.11)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 1.05B

    • Net Income

    • -18.57M

    • Market Cap.

    • 5.10B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 0.75

    • PEG (Price/Earnings Growth) Ratio

    • 1.48

    • Beta

    • 0.75

    • Forward P/E

    • 27.93

    • Price/Sales

    • 4.65

    • Price/Book Value

    • 3.43

    • Price/Cash flow

    • 98.04

      • EBITDA

      • 37.15M

      • Return on Capital %

      • 0.32

      • Return on Equity %

      • 0.66

      • Return on Assets %

      • 0.32

      • Book Value/Share

      • 19.64

      • Shares Outstanding

      • 75.73M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 81.20

        • Credit Rating

        • BBB-

        • Analysts

        • 7

        • EPS Estimate

        • 1.96

        • Cashflow Estimate

        • 3.67

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 13.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • 57.60

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 19.45

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 72.91

            • 82.75

            • Pre-Tax Margin

            • -2.35

            • 39.38

            • Net Profit Margin

            • 0.75

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 76.90

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 15.40

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 9.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.56

              • 0.76

              • Current Ratio

              • 2.83

              • 2.92

              • Quick Ratio

              • 2.26

              • 2.35

              • Interest Coverage

              • 0.49

              • 38.02

              • Leverage Ratio

              • 2.14

              • 2.21

              • Book Value/Share

              • 19.64

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 588.24

                • 238.10

                • P/E Ratio 5-Year High

                • 760.25

                • 634.30

                • P/E Ratio 5-Year Low

                • 152.75

                • 124.82

                • Price/Sales Ratio

                • 4.28

                • 8.94

                • Price/Book Value

                • 3.16

                • 8.12

                • Price/Cash Flow Ratio

                • 98.04

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 0.66

                    (11.40)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 0.32

                    (5.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 2.25

                    (5.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 9.58k

                  • 117.08k

                  • Inventory Turnover

                  • 5.44

                  • 1.48

                  • Asset Turnover

                  • 0.43

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  26.41M
                  Operating Margin
                  2.50
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  98.04
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  53.91%

                  Mutual Fund Ownership

                  64.99%

                  Float

                  79.17%

                  5% / Insider Ownership

                  1.02%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Putnam Capital Spectrum Fund

                  •  

                    4,101,372

                  • 11.26

                  • 5.43

                  • Putnam Equity Spectrum Fund

                  •  

                    1,861,375

                  • 13.04

                  • 2.46

                  • Federated Kaufmann Fund

                  •  

                    1,600,000

                  • -20.00

                  • 2.12

                  • Vanguard Health Care Fund

                  •  

                    1,467,542

                  • 10.91

                  • 1.94

                  • Fidelity® Select Health Care Portfolio

                  •  

                    1,422,640

                  • 1.17

                  • 1.88

                  • Vanguard Small Cap Index

                  •  

                    1,315,521

                  • 0.23

                  • 1.74

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,275,519

                  • 0.00

                  • 1.68

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,227,048

                  • 0.13

                  • 1.62

                  • Dreyfus Opportunistic Midcap Value Fund

                  •  

                    1,119,400

                  • 0.00

                  • 1.48

                  • iShares Core S&P Mid-Cap (AU)

                  •  

                    1,039,075

                  • -4.14

                  • 1.36

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    7,763,044

                  • +6.74%

                  • 10.27

                  • Putnam Investment Management,LLC

                  •  

                    7,432,422

                  • +9.13%

                  • 9.84

                  • Wellington Management Company, LLP

                  •  

                    5,411,728

                  • -1.50%

                  • 7.16

                  • Vanguard Group, Inc.

                  •  

                    4,552,238

                  • +0.72%

                  • 6.02

                  • Westfield Capital Management Company, LP

                  •  

                    3,234,570

                  • +19.88%

                  • 4.28

                  • BlackRock Fund Advisors

                  •  

                    2,982,750

                  • +4.46%

                  • 3.95

                  • Boston Co Asset Management LLC

                  •  

                    2,952,207

                  • +23.39%

                  • 3.91

                  • T. Rowe Price Associates, Inc.

                  •  

                    2,291,443

                  • -1.80%

                  • 3.03

                  • State Street Corp

                  •  

                    2,073,241

                  • +1.47%

                  • 2.74

                  • Federated Global Inv Mgmt Corp

                  •  

                    2,050,490

                  • +652.60%

                  • 2.71

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Mid Growth

                  Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs...more in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peri...morepherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company’s current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.lessless

                  Key People

                  Michael W. Bonney

                  CEO

                  Mr. Kenneth M. Bate

                  Chairman of the Board/Director

                  Mr. Michael Tomsicek

                  CFO/Senior VP/Treasurer

                  Thomas J. DesRosier

                  Chief Administrative Officer/Executive VP/Other Executive Officer

                  Steven C. Gilman,PhD

                  Chief Scientific Officer/Executive VP, Divisional

                  • Cubist Pharmaceuticals Inc

                  • 65 Hayden Avenue

                  • Lexington, MA 02421

                  • USA.Map

                  • Phone: +1 781 860-8660

                  • Fax: -

                  • cubist.com

                  Incorporated

                  1992

                  Employees

                  873

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: